You are here: Home: Audio Program Guide: CCU 4 | 2007: CCU 4 | 2007 Audio
 
  Go to interview with Axel Grothey, MD
Go to interview with Christopher H Crane, MD
Go to interview with Daniel J Sargent, PhD
Go to interview with Aimery de Gramont, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Grothey, MD Axel Grothey, MD
Senior Associate Consultant
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota



  
  Click here to download the entire interview  
Track 1 Strategies to ameliorate oxaliplatin-associated neurotoxicity
Track 2 Combined Oxaliplatin Neurotoxicity Prevention Trial (CONcePT) to optimize first-line FOLFOX with bevacizumab
Track 3 Preliminary analysis of CONcePT: Decreased response to FOLFOX/bevacizumab in patients receiving calcium/magnesium
Track 4 Implications of the CONcePT results
Track 5 Updated efficacy and survival results with adjuvant FOLFOX in the MOSAIC trial
Track 6 Lymph node sampling in colorectal cancer (CRC)
Track 7 Development of molecular tests to aid in treatment decision-making for CRC
Track 8 BRiTE: Exposure to bevacizumab beyond first progression and overall survival among patients with metastatic CRC
Track 9 Intergroup trial SWOG-S0600 (iBET): Irinotecan-based chemotherapy and cetuximab with or without bevacizumab after disease progression on bevacizumab-containing first-line therapy
Track 10 Treatment with bevacizumab beyond disease progression
Track 11 Implications of the negative PACCE trial results with combined bevacizumab and panitumumab
Track 12 Potential explanation for the PACCE trial results
     
Crane, MD Christopher H Crane, MD
Associate Professor
Program Director and Section Chief
Gastrointestinal Section
Department of Radiation Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

  
  Click here to download the entire interview  
Track 1 Phase II study of neoadjuvant chemoradiation therapy with bevacizumab for rectal cancer
Track 2 Outcome of local excision after preoperative chemoradiation therapy among selected patients with T3 rectal cancer
Track 3 Potential mechanisms of action of anti-VEGF therapy
Track 4 Potential effects of bevacizumab on tumor cell signaling
Track 5 Pragmatic physician and patient considerations in the use of capecitabine versus infusional 5-FU
Track 6 X-ACT trial: Efficacy of adjuvant capecitabine versus bolus 5-FU/leucovorin
Track 7 Tolerability of capecitabine-based chemoradiation therapy
Track 8 Capecitabine and the timing of radiation therapy during preoperative chemoradiation for rectal cancer
Track 9 Incorporation of oxaliplatin into chemoradiation therapy for rectal cancer
Track 10 Toxicity with the addition of oxaliplatin to chemoradiation therapy
Track 11 Neoadjuvant study of chemoradiation therapy with capecitabine, erlotinib and bevacizumab for
rectal cancer
Audio
Track 12 Minimization of radiation therapy for patients with rectal cancer
Audio
Track 13 Prognostic factors impacting treatment decision-making in rectal cancer
Audio
Track 14 Clinical management of T1-2 rectal tumors
Audio
Track 15 Biopsy of anal cancer following chemoradiation therapy
Audio
     
Sargent, MD Daniel J Sargent, PhD
NCCTG GI Committee Statistician
NCCTG Group Statistician
Mayo Clinic Cancer Center
Rochester, Minnesota
  
  Click here to download the entire interview  
Track 1 Adjuvant Colon Cancer Endpoints (ACCENT) Group
Track 2 Disease-free survival as a surrogate endpoint for overall survival
Track 3 Perspective on the treatment for Hodgkin’s disease during childhood
Track 4 FDA approval of adjuvant oxaliplatin based on subset analysis of the MOSAIC trial results
Track 5 Commentary on FDA approval of oxaliplatin for adjuvant therapy of Stage III CRC
Track 6 Evolution of the MOSAIC trial results over time
Track 7 Time-dependent patterns of failure and treatment benefit with adjuvant therapy for resectable colon cancer in the ACCENT data set
Track 8 Survival following recurrence among patients with adjuvant colon cancer in the ACCENT data set
Track 9 Applicability of standard statistical approaches to disease-free survival endpoints in clinical trials
Track 10 Potential use of a shorter disease-free survival interval as a surrogate for overall survival
Track 11 Adequacy of lymph node sampling in colon and rectal cancer
Track 12 Perspective on accepting treatment for potentially small benefits

     
de Garamont, MD Aimery de Gramont, MD
Professor of Oncology (Professeur des Universités-Praticien Hospitalier)
Department Head of Internal Medicine — Oncology
Hôpital Saint-Antoine, Paris, France
Paris, France
  
  Click here to download the entire interview  
Track 1 Development of the MOSAIC trial of adjuvant FOLFOX in Stage II and IIl colon cancer
Track 2 Updated six-year efficacy results, including survival, of the MOSAIC trial
Track 3 Benefit of the addition of adjuvant oxaliplatin for patients with Stage II disease
Track 4 Clinical management of oxaliplatin-associated neuropathy
Track 5 Comparison of MOSAIC and NSABP-C-07 outcomes
Track 6 AVANT: Adjuvant FOLFOX versus FOLFOX or XELOX with bevacizumab in colon cancer
Track 7 Considerations in the design and execution of new adjuvant clinical trials in colon cancer
arrow
Track 8 OPTIMOX trials: Evaluation of “treatment holidays” in metastatic disease
arrow
Track 9 BRiTE study: Overall survival with the use of bevacizumab beyond disease progression in metastatic CRC
arrow
Track 10 OPTIMOX-3/DREAM (Double inhibition, Reintroduction, Erlotinib, Avastin, Metastatic CRC) study
arrow